Close
CDMO Safety Testing 2026
Novotech

Dr. Reddy’s announces three generic product launches in the US Market

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Aragen Backs Renaissance Rare Disease Therapy Launch

Contract research, development, and manufacturing organization (CRDMO) Aragen has...

Eli Lilly and Haisco Pharmaceutical Enter $3Billion+ Deal

Eli Lilly has entered into a multi-program collaboration with...

Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi

Eli Lilly and Company and Hanmi Pharm have officially...
- Advertisement -

Dr. Reddy’s Laboratories announced that it has launched the following three products in the US market: Donepezil Hydrochloride tablets (5mg and 10mg strengths), a bioequivalent generic version of ARICEPT® tablets*. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Donepezil HCl tablets on May 31, 2011. Both strengths of Dr. Reddy’s Donepezil Hydrochloride tablets are available in 30, 90 and 500 count bottles.

Venlafaxine Hydrochloride Extended Release capsules (37.5mg, 75mg and 150mg strengths), a bioequivalent generic version of EFFEXOR XR® Extended Release capsules**. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Venlafaxine Hydrochloride Extended Release Capsules on May 05, 2011. All three strengths of Dr. Reddy’s Venlafaxine Hydrochloride Extended Release Capsules are available in 30, 90 and 500 count bottles.

Letrozole tablets, USP (2.5mg), a bioequivalent generic version of FEMARA®***. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Letrozole tablets, USP on June 3, 2011. Dr. Reddy’s Letrozole tablets, USP are available in 30 count bottles.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Aragen Backs Renaissance Rare Disease Therapy Launch

Contract research, development, and manufacturing organization (CRDMO) Aragen has...

Eli Lilly and Haisco Pharmaceutical Enter $3Billion+ Deal

Eli Lilly has entered into a multi-program collaboration with...

Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi

Eli Lilly and Company and Hanmi Pharm have officially...

Pharmacogenomics in 2026: From Research Concept to Clinical Workflow

Pharmacogenomics has moved well beyond the research phase. In...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »